Dr Reddy’s Laboratories shares extended their decline after the company delayed commercial supplies of its semaglutide product due to a quality-related API issue. While brokerages remain broadly positive on the long-term outlook, several have cut target prices and earnings estimates, citing near-term execution risks and slower product ramp-up.
India’s weight in global emerging-market ETFs rises again
India’s weight in major global emerging-market ETFs has begun to recover recently. This rise follows a steady decline over the past year, showing improved performance.
August 25, 2026